Screener
ImmunityBio, Inc. IBRX Change in fair value of derivative liabilities
Change in fair value of derivative liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ChangeInFairValueOfDerivativeLiabilities.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s change in fair value of derivative liabilities?
- ImmunityBio, Inc. (IBRX) reported change in fair value of derivative liabilities of -$1.11M in Q1 2026.
- How has ImmunityBio, Inc.'s change in fair value of derivative liabilities changed year-over-year?
- ImmunityBio, Inc.'s change in fair value of derivative liabilities increased by 80.1% year-over-year, from -$5.58M to -$1.11M.
- What does change in fair value of derivative liabilities mean?
- This metric captures the periodic adjustment in the valuation of derivative instruments classified as liabilities on the balance sheet. These fluctuations are driven by changes in market conditions, such as stock price volatility or interest rates, and are non-cash in nature.
Ask your AI about ImmunityBio, Inc.'s change in fair value of derivative liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude